MedTrace Logo

Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities

NCT06662539 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 493

Last updated 2026-03-23

No results posted yet for this study

Summary

The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.

Conditions

Interventions

DRUG

Petrelintide

Petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.

DRUG

Placebo

Matching placebo to petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-09
Primary Completion
2025-09-30
Completion
2026-03-07
FDA Drug
Yes

Countries

  • United States
  • Poland
  • Romania

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06662539 on ClinicalTrials.gov